Sanofi (NASDAQ:SNY) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in shares of Sanofi (NASDAQ:SNY) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 257,655 shares of the company’s stock after purchasing an additional 2,917 shares during the quarter. Geode Capital Management LLC’s holdings in Sanofi were worth $12,427,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Diametric Capital LP purchased a new stake in shares of Sanofi in the 4th quarter valued at about $214,000. National Bank of Canada FI boosted its holdings in shares of Sanofi by 2.0% in the fourth quarter. National Bank of Canada FI now owns 303,934 shares of the company’s stock valued at $14,659,000 after acquiring an additional 6,089 shares during the period. HighPoint Advisor Group LLC increased its holdings in shares of Sanofi by 7.2% in the 4th quarter. HighPoint Advisor Group LLC now owns 8,985 shares of the company’s stock valued at $433,000 after acquiring an additional 601 shares during the period. Franklin Resources Inc. raised its position in Sanofi by 10.8% in the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company’s stock valued at $182,164,000 after purchasing an additional 369,530 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Sanofi by 19.8% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,175 shares of the company’s stock worth $156,000 after purchasing an additional 525 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

SNY stock opened at $50.93 on Tuesday. The stock’s 50 day moving average price is $54.65 and its 200 day moving average price is $52.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The firm has a market cap of $128.66 billion, a P/E ratio of 20.45, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a $2.0369 dividend. This is an increase from Sanofi’s previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. Sanofi’s dividend payout ratio (DPR) is 64.26%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price on the stock. Three analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.